MarketLens
Sign Up

Why is Eli Lilly Betting on Shingles Vaccines

4 months ago
SHARE THIS ON:

Why is Eli Lilly Betting on Shingles Vaccines

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•3 days ago

Eli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock

Eli Lilly's largest shareholder filed to sell ~$347M of stock, even as analysts keep raising price targets. The opposing signals leave investors weighing insider supply against bullish Street revision...
Stock News•1 week ago

Vaxcyte Stock Spikes 57% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Vaxcyte shares spiked 57% after trial results for its lead vaccine candidate, which Jefferies says positions it to capture share of a $3B–$6B market.
Stock News•1 months ago

Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s

Eli Lilly's immunology portfolio is gaining ground with steady revenue growth, pipeline expansion, and acquisitions, broadening its next wave of growth beyond GLP-1s.

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today

Stock News•1 hour ago

Why the Market Dipped But Microsoft (MSFT) Gained Today

Stock News•1 hour ago

Nvidia (NVDA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Stock News•1 hour ago

Tesla (TSLA) Declines More Than Market: Some Information for Investors

Stock News•1 hour ago

Amazon Will Be The Final Winner Of The AI Race With Anthropic's Help